EFG Asset Management North America Corp. Reduces Holdings in Stryker Co. (NYSE:SYK)

EFG Asset Management North America Corp. decreased its stake in Stryker Co. (NYSE:SYK - Free Report) by 13.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 8,397 shares of the medical technology company's stock after selling 1,305 shares during the period. EFG Asset Management North America Corp.'s holdings in Stryker were worth $3,024,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Vanguard Group Inc. lifted its stake in Stryker by 0.8% during the fourth quarter. Vanguard Group Inc. now owns 32,698,828 shares of the medical technology company's stock worth $11,773,213,000 after purchasing an additional 252,188 shares during the last quarter. State Street Corp raised its holdings in shares of Stryker by 2.2% during the 3rd quarter. State Street Corp now owns 14,582,959 shares of the medical technology company's stock valued at $5,279,788,000 after buying an additional 316,404 shares in the last quarter. FMR LLC lifted its position in Stryker by 3.0% in the 3rd quarter. FMR LLC now owns 7,306,994 shares of the medical technology company's stock worth $2,639,725,000 after buying an additional 215,782 shares during the last quarter. Geode Capital Management LLC boosted its stake in Stryker by 2.5% in the third quarter. Geode Capital Management LLC now owns 6,905,126 shares of the medical technology company's stock worth $2,484,893,000 after buying an additional 165,490 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. grew its holdings in shares of Stryker by 2.5% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,985,045 shares of the medical technology company's stock valued at $714,715,000 after purchasing an additional 48,819 shares during the last quarter. Hedge funds and other institutional investors own 77.09% of the company's stock.

Remove Ads

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on SYK shares. Wells Fargo & Company raised their price target on Stryker from $427.00 to $435.00 and gave the stock an "overweight" rating in a research report on Wednesday, January 29th. Royal Bank of Canada lifted their target price on shares of Stryker from $425.00 to $435.00 and gave the stock an "outperform" rating in a research note on Wednesday, January 29th. Stifel Nicolaus increased their price target on shares of Stryker from $400.00 to $440.00 and gave the company a "buy" rating in a research report on Wednesday, January 29th. Canaccord Genuity Group boosted their price objective on shares of Stryker from $420.00 to $435.00 and gave the company a "buy" rating in a research report on Wednesday, January 29th. Finally, Morgan Stanley upgraded shares of Stryker from an "equal weight" rating to an "overweight" rating and increased their target price for the stock from $370.00 to $445.00 in a report on Monday, December 2nd. Five research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company's stock. According to MarketBeat, Stryker has an average rating of "Moderate Buy" and a consensus target price of $421.90.

Insider Buying and Selling

In other news, Director Ronda E. Stryker sold 201,392 shares of the business's stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the completion of the transaction, the director now directly owns 3,642,075 shares of the company's stock, valued at $1,428,567,498. The trade was a 5.24 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Allan C. Golston sold 2,458 shares of the firm's stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total transaction of $941,586.06. Following the completion of the sale, the director now owns 14,895 shares in the company, valued at $5,705,827.65. This represents a 14.16 % decrease in their position. The disclosure for this sale can be found here. 5.90% of the stock is owned by company insiders.

Stryker Stock Down 0.9 %

Shares of SYK stock traded down $3.16 during trading hours on Friday, hitting $364.38. 1,274,307 shares of the company's stock traded hands, compared to its average volume of 1,289,456. The company has a quick ratio of 1.32, a current ratio of 1.95 and a debt-to-equity ratio of 0.59. The stock has a market cap of $139.08 billion, a price-to-earnings ratio of 46.96, a PEG ratio of 2.93 and a beta of 0.95. The stock's fifty day simple moving average is $384.08 and its two-hundred day simple moving average is $374.32. Stryker Co. has a 12-month low of $314.93 and a 12-month high of $406.19.

Stryker (NYSE:SYK - Get Free Report) last released its earnings results on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, topping the consensus estimate of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same period in the prior year, the business earned $3.46 EPS. On average, analysts expect that Stryker Co. will post 13.47 EPS for the current year.

Stryker Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be given a dividend of $0.84 per share. This represents a $3.36 annualized dividend and a dividend yield of 0.92%. The ex-dividend date of this dividend is Monday, March 31st. Stryker's dividend payout ratio (DPR) is currently 43.30%.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.